Analysis | N | 0 months | 6 months | 0–6 month difference | |
---|---|---|---|---|---|
 |  | Mean (SD) | Mean (SD) | Mean (95%-CI) | P-value |
Main analysis: Patients with evaluable Symptom Score at 0 and 6 months | 381 | 6.21 (1.76) | 3.80 (2.34) | 2.41 (2.16–2.66) | < 0.001 |
SA1: Last value carried forward | 433 | 6.15 (1.80) | 3.87 (2.35) | 2.28 (2.05–2.52) | < 0.001 |
SA2: Patients with disease duration ≥ 12 months at study enrolment | 320 | 6.29 (1.76) | 3.91 (2.28) | 2.39 (2.13–2.65) | < 0.001 |
SA1 + SA2 | 364 | 6.24 (1.78) | 3.96 (2.30) | 2.28 (2.03–2.52) | < 0.001 |
Patients with main diagnosis of mental, musculoskeletal or respiratory diseases, headache disorders or urinary incontinence | Â | Â | Â | Â | Â |
Main analysis: Patients with evaluable Symptom Score at 0 and 6 months | 297 | 6.26 (1.72) | 3.84 (2.35) | 2.42 (2.13–2.71) | < 0.001 |
SA3: Patients not using diagnosis-related non-anthroposophic therapies (see Table 1) in months 0–6 | 239 | 6.32 (1.71) | 3.69 (2.29) | 2.63 (2.32–2.95) | < 0.001 |
SA1 + SA2 + SA3 | 204 | 6.40 (1.71) | 3.87 (2.21) | 2.54 (2.22–2.86) | < 0.001 |